INITIATOR PHARMA: PREPARING FOR THE CLINICAL PHASE
Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016. Because of this, comparing numbers refer to the time period 2016-05-02 – 2016-12-31.
|Fourth Quarter (2017-10-01 – 2017-12-31)|
|Full Year (2017-01-01 – 2017-12-31)|
Group earnings per share: period result divided by a number of 8 683 943 stocks (on 2017-12-31). Solidity: equity divided by assets.
Business highlights in Q4 2017
Significant events after this reporting period
Comments from the CEO
”In Q4 Initiator Pharma obtained positive data from the toxicologic and toxicokinetic animal studies and in January we announced the successful completion of the preclinical development of IPED2015. The recent advances means that we can now implement our plans for the start of clinical Phase 1 studies in humans in the middle of this year. In order to fund these plans the board of directors has decided to conduct a preferential rights issue. It is the company´s ambition that if Extraordinary Assembly to be held on March 1 approves the proposal and if the share issue as well as the warrant program TO1 is fully subscribed the company will be fully funded to complete the clinical Phase IIa proof of concept for IPED2015.
For more information, please contact
Claus Olesen, CEO, Initiator Pharma, Mobile: +45-61 26 00 35, E-mail: email@example.com
Torgeir Vaage, CFO, Initiator Pharma, Mobile: +47-924 05 235, E-mail: firstname.lastname@example.org
About Initiator Pharma
Initiator Pharma A/S is a Danish biotechnology company focusing on the development of innovative drugs, targeting key unmet medical needs within the central and peripheral nervous system. Our research is focusing on monoamine reuptake inhibitors, molecules that are affecting the synaptic concentrations of neurotransmitters such as dopamine, serotonin and noradrenaline. Our lead drug candidate, IPED2015 is targeting the medical condition Erectile Dysfunction (ED), and specifically patients with ED that are non-responsive to drugs within the PDE5i class, including the approved drugs ViagraÓ, CialisÓ and LevitraÓ.
Initiator Pharma is based in Aarhus, Denmark. Initiator Pharma is listed on Aktietorget and has about 3.600 shareholders. Read more at www.initiatorpharma.com.